CULVER CITY, Calif.--(BUSINESS WIRE)--Jun. 6, 2019--
today announced the appointment of Cheryl L. Cohen to the Board of
Directors of NantKwest, effective immediately.
“Cheryl is a proven business executive and highly experienced board
member in both the biotechnology and pharmaceutical sectors,” said
Patrick Soon-Shiong, Chairman and CEO of NantKwest. “We are very pleased
to welcome such an accomplished business leader and are confident that
her strategic perspective and operational expertise will add significant
value to our Board of Directors.”
Since 2008, Ms. Cohen has served as president of CLC Consulting, a
pharmaceutical and biotechnology consulting firm specializing in new
product start-up and commercialization.
Prior to CLC, Ms. Cohen served as chief commercial officer of
Medivation, Inc., a publicly-traded bio-pharmaceutical company, from
September 2011 until July 2014. From November 2007 to September 2008,
she served as the vice president, strategic commercial group, of Health
Care Systems, Inc., a Johnson & Johnson company, and from October 1998
to November 2007, she worked at Janssen Biotech, Inc. (formerly Centocor
Biotech, Inc.), a Johnson & Johnson company, in a variety of senior
sales roles including vice president, rheumatology franchise.
In addition, Ms. Cohen served on the board of Aerpio Pharmaceuticals,
Inc., a pharmaceutical company, since 2018 and also served on the board
of Vital Therapies, Inc., a therapeutics company, from 2015 until 2019.
Since 2015, Ms. Cohen has served on the board of Novus Therapeutics,
Inc. (reverse merger of Tokai Pharmaceuticals, Inc.), a publicly-traded
pharmaceutical company focused on the acquisition, development, and
commercialization of ear, nose, and throat products and served on the
board of Protein Sciences Corporation, a privately held
bio-pharmaceutical company specializing in vaccine development from
October 2014 to August 2017. She served on the board of Cytrx
Corporation, a publicly traded bio-pharmaceutical company specializing
in oncology, from June 2015 through October 2016.
Ms. Cohen began her career at Solvay Pharmaceuticals in a variety of
sales positions and received her B.A. from Saint Joseph College.
For additional information, please visit, www.nantkwest.com.
NantKwest, a member of the NantWorks ecosystem of companies, is an
innovative clinical-stage immunotherapy company focused on harnessing
the power of the innate immune system by using the natural killer cell
to treat cancer and virally induced infectious diseases.
NantKwest is uniquely positioned to implement precision cancer medicine,
with the potential to change the current paradigm of cancer care.
Natural Killer (NK) cells are a safeguard in the human body designed to
recognize and detect cells under stress due to cancer or viral
infection. NantKwest’s “off-the-shelf” activated NK cell platform is
designed to destroy cancer and virally infected cells from the body. The
safety of our NK cells as well as their activity against a broad range
of cancers have been tested in phase I clinical trials in Canada and
Europe as well as in multiple phase I and II clinical trials in the
United States. In addition to being a universal cell-based therapy that
does not require individualized patient sourcing or matching, our NK
cell products have been largely administered in the outpatient setting
as an “off-the-shelf” living drug.
With the capacity to grow active killer cells as a cancer therapy, our
NK cells have been designed to induce cell death against cancers and
virally infected cells by several mechanisms, including: (i) innate
killing, whereby all of our NK platforms recognize the stress proteins
typically found on cancer cells, which, upon binding, release toxic
granules to immediately kill their targets; (ii) antibody-mediated
killing with our haNK® platform, which are NK cells engineered to
express antibody receptors that can bind to therapeutic antibody
products, thereby enhancing the cancer cell killing effect of that
antibody; and (iii) Chimeric Antigen Receptor directed killing using the
taNK® platform, which includes NK cells engineered to incorporate
chimeric antigen receptors (CARs) to target tumor-specific antigens
found on the surface of cancer cells. All three modes of killing
(innate, antibody-mediated, and CAR directed killing) are employed by
our t-haNK™ platform, which is an innovative combination of our aNK,
haNK® and taNK® platforms in a single product.
Our haNK®, and t-haNK™ platforms have been designed to address certain
limitations of CAR T-cell therapy including the capability to infuse
cell therapy in an outpatient setting which allows for potential
reduction of risk for serious cytokine storms and protracted serious
adverse events. In Phase I and II clinical trials in patients with late
stage cancer, our NK cells have been administered as an investigational
outpatient infusion safely with greater than 500 infusions to date at a
dose of 2 billion cells per infusion.
By leveraging an integrated and extensive genomics and transcriptomics
discovery and development engine, together with a pipeline of multiple,
clinical-stage, immuno-oncology programs, we believe NantKwest is
uniquely positioned to be the premier immunotherapy company and
transform medicine by delivering living drugs in a bag and bringing
novel NK cell-based therapies to routine clinical care.
NK-92, aNK, haNK, taNK, and t-haNK are trademarks of NantKwest, Inc.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning or implying
that NantKwest will be successful in improving the treatment of cancer.
Risks and uncertainties related to this endeavor include, but are not
limited to, obtaining FDA approval of NantKwest’s NK cells as well as
other therapeutics as part of the NANT Cancer Vaccine platform as a
Forward-looking statements are based on management's current
expectations and are subject to various risks and uncertainties that
could cause actual results to differ materially and adversely from those
expressed or implied by such forward-looking statements. Accordingly,
these forward-looking statements do not constitute guarantees of future
performance, and you are cautioned not to place undue reliance on these
These and other risks regarding NantKwest’s business are described in
detail in its Securities and Exchange Commission filings, including in
NantKwest’s Quarterly Report on Form 10-Q for the quarter ended March
31, 2019. These forward-looking statements speak only as of the date
hereof, and we disclaim any obligation to update these statements except
as may be required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190606005809/en/